CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Open-market sale Chief Financial Officer sold 4,800 shares at an average $30.01 ($144,028)
- 4 Grant or award Director acquired 6,020 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Grant or award Director acquired 3,010 shares (grant or award)
- 4 Exercise or conversion Chief Financial Officer acquired 29,900 shares (option exercise)
- 4 Grant or award Chief Financial Officer acquired 8,900 shares (grant or award)
- 4 Shares withheld for taxes Chief Oper. & Tech. Officer gave up 1,332 shares (to pay taxes)
- 4 Open-market sale Chief Medical Officer sold 1,598 shares at $33.75 ($53,933)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 1,221 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Legal Officer gave up 1,332 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 3,636 shares (to pay taxes)
- 4 Open-market sale Director sold 112,869 shares at an average $34.69 ($3,915,359)
- 4 Gift President and CEO gave 3,300 shares (gift)
- 4 Open-market sale President and CEO sold 1,500 shares at $40.00 ($60,000)
Page 7 of 22 · 435 filings